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OBJECTIVE: In the present study, the peripheral mechanism that mediates the pressor effect of angiotensin-(1-7)
in the rostral ventrolateral medulla was investigated.
METHOD: Angiotensin-(1-7) (25 pmol) was bilaterally microinjected in the rostral ventrolateral medulla near the
ventral surface in urethane-anesthetized male Wistar rats that were untreated or treated (intravenously) with
effective doses of selective autonomic receptor antagonists (atenolol, prazosin, methyl-atropine, and
hexamethonium) or a vasopressin V1 receptor antagonist [d(CH2)5 -Tyr(Me)–AVP] given alone or in
combination.
RESULTS: Unexpectedly, the pressor response produced by angiotensin-(1-7) (16¡2 mmHg, n = 12), which was
not associated with significant changes in heart rate, was not significantly altered by peripheral treatment with
prazosin, the vasopressin V1 receptor antagonist, hexamethonium or methyl-atropine. Similar results were
obtained in experiments that tested the association of prazosin and atenolol; methyl-atropine and the
vasopressin V1 antagonist or methyl-atropine and prazosin. Peripheral treatment with the combination of
prazosin, atenolol and the vasopressin V1 antagonist abolished the pressor effect of glutamate; however, this
treatment produced only a small decrease in the pressor effect of angiotensin-(1-7) at the rostral ventrolateral
medulla. The combination of hexamethonium with the vasopressin V1 receptor antagonist or the combination
of prazosin, atenolol, the vasopressin V1 receptor antagonist and methyl-atropine was effective in blocking the
effect of angiotensin-(1-7) at the rostral ventrolateral medulla.
CONCLUSION: These results indicate that angiotensin-(1-7) triggers a complex pressor response at the rostral
ventrolateral medulla that involves an increase in sympathetic tonus, release of vasopressin and possibly the
inhibition of a vasodilatory mechanism.
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& INTRODUCTION
The rostral ventrolateral medulla (RVLM) is well known
as a key region in the central nervous system (CNS) for the
tonic and reflex control of circulation (1), especially because
it is considered to be the main source of the excitatory
activation of sympathetic pre-ganglionic neurons that
innervate the cardiovascular system (2,3). In addition, it is
well accepted that the pressor response evoked by stimula-
tion of neurons in the RVLM is caused by an increase in the
total peripheral resistance that results mainly from the
widespread stimulation of sympathetic vasomotor activity
(4-6).
The RVLM has been identified as a site in the CNS where
angiotensin (Ang) peptides may modulate arterial pressure
(7-9). Currently, Ang II and Ang-(1-7) are recognized as the
main effectors of the renin-angiotensin system (RAS) in
different tissues and in the brain (10-12). The Ang selective
receptors AT1 and Mas (13) are widely distributed in the
CNS, especially in the areas related to cardiovascular
control, including the RVLM (7,14,15). Microinjection of
Ang II or Ang-(1-7) into the RVLM produces increases in
arterial pressure in different species, especially in anesthe-
tized (16) or conscious rats (17,18), which suggests that these
peptides function as excitatory modulators in this region.
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The pressor effects of these peptides are selectively blocked
by losartan, which is an AT1 receptor antagonist, or A-779,
which is a Mas receptor antagonist (19). Furthermore,
bilateral microinjection of the selective Ang-(1-7) antagonist
A-779 into the RVLM produces a sustained reduction in the
mean arterial pressure and heart rate (17), whereas micro-
injection of losartan, which is an AT1 receptor antagonist,
does not affect arterial pressure (18,20,21). The pressor effect
produced by Ang II at the RVLM is attributed to an increase
in sympathetic activity at the periphery (9). In the present
study, we evaluated the peripheral mechanism responsible
for mediating the pressor effect produced by bilateral
microinjection of Ang-(1-7) at the RVLM by using selective
autonomic receptor blockers and a vasopressin V1 receptor
antagonist.
& MATERIAL AND METHODS
All experiments were conducted in accordance to the
National Institutes of Health guide for the care and use of
laboratory animals (NIH Publications No. 85-23, revised
1996) and the Comite de Etica em Experimentac¸a˜o Animal/
Universidade Federal de Minas Gerais (CETEA/UFMG;
http://www.ufmg.br/bioetica/cetea/).
Surgical procedures
The experiments were performed using 119 maleWistar rats
(260-280 g) that were anesthetized with urethane (1.4 g/kg i.p,
Sigma Chemical Co, St. Louis, MO, USA). A tracheostomy was
performed, and catheters were inserted into the abdominal
aorta through the femoral artery and into the inferior cava vein
through the femoral vein for the measurement of arterial
pressure and injection of drugs, respectively. The animals were
then placed in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA) with the tooth bar 11 mm below the level
of the interaural line. The dorsal surface of the brainstem was
exposed by a limited occipital craniotomy and incision of the
atlanto-occiptal membrane as previously described (16).
Arterial pressure measurements
Arterial pressure and heart rate (HR) were continuously
monitored using a solid-state strain gauge transducer coupled
to a Nihon–Kohden polygraph (Tokyo, Japan) or a blood
pressure signal amplifier (Stemtech, Inc.–Quintron, Milwaukee,
WI, USA) connected to a data acquisition system (Codas
Instruments, Akron, OH, USA) with a 600-Hz sampling rate.
Microinjection procedures
Simultaneous bilateral microinjections of Ang-(1-7) or
sterile saline (vehicle; 0.9% NaCl) in a volume of 200 nl were
performed over a 20-30-s period into the rostral ventrolat-
eral medulla (RVLM: 2.0 mm anterior, 1.8 mm lateral to the
obex) in the ventral surface just above the pia mater, as
previously described (16). The microinjections were per-
formed using Hamilton syringes fitted with metallic needles
(injector needles, 30-gauge) and polyethylene tubing. The
injector needle was introduced through a guide cannula (22-
gauge) that was fixed to the stereotaxic manipulator. Only
the injector needles were inserted into the brain tissue
through the dorsal surface. The experiments were per-
formed only at sites where the positioning of the injector
needle produced a transient mechanical pressor response, as
we previously found this to be an indication of the correct
placement into the RVLM (16). In all animals, a minimum
time interval of 20 minutes was given between the
positioning the injector needles and the beginning of the
experiments (peripheral treatment and/or RVLM micro-
injection).
Experimental Protocols
1. Cardiovascular effects of Ang-(1-7) at the RVLM. The
effects on arterial pressure and heart rate produced by
RVLM bilateral microinjection of saline (200 nl, n = 5) or
Ang-(1-7) in different animals at doses of 2.5 pmol (n = 4),
12.5 pmol (n = 7), 25 pmol (n = 12) or 50 pmol (n = 5) were
evaluated.
2. Cardiovascular effects of Ang-(1-7) after peripheral
blockade of the autonomic nervous system and/or
vasopressin antagonism. The effects on arterial pressure
and heart rate produced by bilateral microinjection of Ang-(1-
7) (25 pmol) into the RVLMwere evaluated after intravenous
treatment with: 1) the b1-adrenergic receptor antagonist
atenolol, 2.5 mg/kg (n= 6); 2) the a1-adrenergic receptor
antagonist prazosin, 90 mg/kg (n= 7); 3) the muscarinic
receptor antagonist methyl-atropine (M-atropine; 2.0 mg/kg,
n= 5); 4) the ganglionic blocking agent hexamethonium,
20 mg/kg (n= 8); 5) the vasopressin V1 receptor antagonist
[d(CH2)5-Tyr(Me)-AVP] (VPa), 10 mg/kg (n= 7); 6) 90 mg/kg
prazosin combinedwith 2.5 mg/kg atenolol, (n= 6); 7) 90 mg/
kg prazosin combined with 2.0 mg/kg M-atropine (n= 6); 8)
2.0 mg/kg M-atropine combined with 10 mg/kg VPa (n= 4);
9) 90 mg/kg prazosin combined with 2.5 mg/kg atenolol and
10 mg/kg VPa (n= 7); 10) 90 mg/kg prazosin combined with
2.5 mg/kg atenolol and 10 mg/kg VPa, and 2.0 mg/kg M-
atropine (n= 5) or 11) 20 mg/kg hexamethonium combined
with 10 mg/kg VPa (n= 7). In another group of animals,
effects on arterial pressure and HR produced by bilateral
microinjection of glutamate (20 nmoles) were observed
before and 20 minutes after peripheral treatment with 90
mg/kg prazosin combined with 2.5 mg/kg atenolol, and 10
mg/kg VPa (n= 4).
To control for non-specific effects produced by the
injection volume and/or tissue damage we evaluated the
effects on arterial pressure and HR produced by bilateral
microinjection of vehicle (saline; 0.9% NaCl, 200 nl) into the
RVLM of additional animals, following peripheral treat-
ment with: 1) 90 mg/kg prazosin (n = 6); 2) 10 mg/kg VPa
(n = 2); 3) 90 mg/kg prazosin combined with 2.5 mg/kg
atenolol and 10 mg/kg VPa (n = 3); 4) 90 mg/kg prazosin
combined with 2.5 mg/kg atenolol, 10 mg/kg VPa and
2.0 mg/kg M-atropine (n = 3). Saline was microinjected into
the RVLM 5-20 minutes after the intravenous treatment.
Histological verification of injection sites:
At the end of each experiment, in all animals, the injector
needles were withdrawn and replaced by a pair of needles
containing Alcian blue dye (5%). The ventromedullary sites
were marked by the injection of 200 nl of the dye, bilaterally.
The brain was then carefully removed and fixed in 10%
phosphate-buffered formalin. Serial coronal sections (25-50
mm) of the medulla oblongata were obtained and stained
with neutral red. The microinjection sites were identified by
the deposition of Alcian blue dye using light microscopy
and referred to standard anatomical structures of the brain
stem according to the atlas of Paxinos & Watson (22).
Drugs
Ang-(1-7), glutamate, VPa and the autonomic blockers
were dissolved in sterile isotonic saline (NaCl, 0.9%)
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immediately before use. Ang-(1-7) was purchased from
Bachem (Torrance, CA, USA), and the autonomic receptor
blockers, glutamate and VPa [d(CH2)5-Tyr(Me)-AVP] were
purchased from Sigma Chemical Company (St. Louis, MO,
USA). The doses of the autonomic blockers and VPa were
chosen based on preliminary experiments that showed that
the selected doses abolished the cardiovascular effects
produced by each specific agonist for up to 60 min. In
addition, the degree of blockade was evaluated in the
majority of the animals at the end of each experiment.
Statistical analysis
The results are expressed as the means¡SEM. The
measured parameters before and after injection in the same
animal were compared using Student’s t-test for paired
observations. Multiple groups were compared using
ANOVA followed by the Newman-Keuls test. All data
analysis was performed using the statistics program PRISM
(Graphpad Prism Software, version 4.0; San Diego, CA,
USA). The criterion for statistical significance was p,0.05.
& RESULTS
Cardiovascular effects of Ang-(1-7) at the RVLM
Microinjection of Ang-(1-7) into the RVLM produced a
shallow dose-dependent increase in MAP ranging from
11¡2 mmHg with a dose of 2.5 pmol (duration: 9¡2
minutes) to 19¡4 mmHg with a dose of 50 pmol (duration:
24¡9 minutes) (Table 1), as we have shown in previous
studies (16,17). The changes in blood pressure were
significantly different from the changes produced by the
vehicle (change in MAP: 4¡1 mmHg, duration: 6¡2
minutes; n = 5, ANOVA followed by Newman-Keuls test).
The pressor effect produced by Ang-(1-7) was not accom-
panied by consistent changes in HR (Table 1).
Cardiovascular effects of Ang-(1-7) at the RVLM
after peripheral selective autonomic blockade
Table 2 shows the baseline values of the MAP and HR
before and after the administration of different blockers or
receptor antagonists. As expected, pre-treatment with the
a1-adrenergic receptor antagonist prazosin or the ganglionic
blocker hexamethonium produced a sustained decrease in
MAP (Table 2). A significant decrease in HR was also
observed after hexamethonium administration (Table 2).
Atenolol or M-atropine produced significant changes in the
baseline HR that were not accompanied by changes in the
baseline values of MAP (Table 2). Surprisingly, none of
these peripheral treatments alone significantly affected the
magnitude or duration (data not shown) of the pressor
response produced by the injection of 25 pmol of Ang-(1-7)
into the RVLM (16¡2 mmHg, control animals, n = 12;
Figure 1).
Cardiovascular effects of Ang-(1-7) in the RVLM
after treatment with a VP V1 antagonist
Pre-treatment with VPa did not significantly change the
baseline values of MAP (Table 2) or significantly modify the
increase in MAP induced by the microinjection of Ang-(1-7)
into the RVLM (14¡3 mmHg, n= 6 in comparison to
16¡2 mmHg of control rats, n = 12; Figure 1). Treatment
with VPa produced a tendency to decrease the duration of
the Ang-(1-7) MAP effect; however, the difference was not
statistically significant (8.4¡1.9 min in comparison to
14¡3 min in control rats; p.0.05, Student’s t-test; data not
shown).
Cardiovascular effects of Ang-(1-7) in the RVLM
after treatment with combinations of different
autonomic blockers and a VP V1 antagonist
The combination of different blockers of the autonomic
nervous system produced the expected changes in the
baseline MAP and HR as shown in Table 2. The combination
of a1 (prazosin) and b1 (atenolol) adrenergic blockade
(Figures 2A and 3A) did not significantly affect the
magnitude or duration of the pressor effect of Ang-(1-7).
The combination of a1 adrenergic blockade (prazosin) and
muscarinic receptor blockade (M-atropine) or the combina-
tion of M-atropine and the VP V1 receptor antagonist tended
to reduce (,30%) the magnitude (Figure 3A) of the pressor
effect of Ang-(1-7) in the RVLM. However, the pressor effect
was not significantly different from that observed after Ang-
(1-7) microinjection in non-treated rats. The combination of
a1- and b1-adrenergic blockade with VPa, which abolishes
the pressor effect induced by the injection of 20 nmol of
glutamate in the RVLM (1.2¡1.1 mmHg in comparison to
25¡2 mmHg before treatment, n = 4; data not shown) did
not significantly influence the pressor effect of Ang-(1-7) in
the RVLM (13¡1 mmHg, n = 5 in comparison to
16¡2 mmHg in untreated rats, n = 12; Figures 2B and 3B).
Only the pre-treatment with the combination of a1 and b1
adrenergic blockade, M-atropine and VPa was able to
effectively abolish the pressor action of Ang-(1-7) in the
RVLM (Figures 2C and 3B). In addition, the pressor effect of
Ang-(1-7) was significantly reduced by the combination of
ganglionic blockade with hexamethonium and VPa
(Figure 3B). Similarly to control rats, no significant changes
Table 1 - Baseline values for the mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/min) as well as MAP and








n MAP (mmHg) HR (beats/min)
Saline, 200 nl 5 100¡5 334¡20 4¡1 6¡2 -3¡3.0
Ang-(1-7)
2.5 pmol 4 109¡6 375¡20 11¡2 9¡2 1¡2.5
12.5 pmol 7 106¡6 336¡6 15¡3* 21¡2* -3¡10
25.0 pmol 12 108¡5 339¡8 14¡1* 14¡3* -5¡12
50.0 pmol 5 106¡9 323¡22 19¡4* 25¡9* -2¡25
*p,0.05 in comparison to the saline control group (ANOVA followed by Dunnet’s test).
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in HR were observed after Ang-(1-7) microinjection in
treated animals (data not shown).
Microinjection of saline into the RVLM of animals treated
with autonomic receptor antagonists and/or VPa produced
similar increases in MAP that were averaged together (MAP
changes= 5.5¡0.8 mmHg, n= 14; data not shown). These
changes were not significantly different from those observed
in non-treated animals (4¡1 mmHg, n= 5; Table 1).
Histological examination
As shown by the composite of the injection sites shown in
Figure 4, the deposition of Alcian Blue dye (Sigma-Aldrich, St
Louis, MO, USA) in all animals used in this study was
confined to the ventral portion of the lateral paragigantocel-
lular nucleus and the rostroventrolateral reticular nucleus.
& DISCUSSION
In the present study, we showed that the pressor effect
induced by bilateral microinjection of Ang-(1-7) into the
RVLM is not solely dependent on an increase in sympathetic
drive; it also depends on the release of AVP and on the
inhibition of the vasodilator mechanism. This conclusion
was based on the following observations: 1) The effect of
Ang-(1-7) was not affected by isolated peripheral treatment
with a1 or b1 adrenergic blockade, VP V1 receptor antagon-
ism, or even with a ganglionic inhibitor alone; 2) The
combination of a1 and b1 adrenergic blockade with an AVP
V1 receptor antagonist, which abolished the effect of
glutamate, did not affect the pressor effect of Ang-(1-7);
and 3) Only the combination of a1 and b1 adrenergic
blockade with cholinergic blockade and a VP V1 receptor
antagonist or the combination of ganglionic blockade with a
VP V1 receptor antagonist completely abolished the pressor
effect of Ang-(1-7).
The pressor effect produced by Ang-(1-7) at the RVLM is
consistent with that described previously in anesthetized
(16,17) or conscious rats (18). The lack of a clear dose-
response curve is compatible with the well-known neuro-
modulatory effect of peptides (9,23). The finding that the
Ang-(1-7) pressor effect was not accompanied by consistent
changes in HR even in the presence of B1 receptor blockade
indirectly suggests that a reduction in the vagal activity in
the heart is not an important component for the pressor
effect of Ang-(1-7). This finding agrees with our previous
studies (16-18), and it is also a common observation after
microinjection of Ang II in this region (7-9,24).
Surprisingly, the peripheral administration of the a1
adrenergic receptor antagonist prazosin or the b1 adrenergic
receptor antagonist atenolol alone or in combination did not
modify the pressor effect of Ang-(1-7). Moreover, the
administration of hexamethonium, which is a ganglionic
blocking drug, did not affect the activity of Ang-(1-7) at the
RVLM. These results show that an isolated increase in
sympathetic activity does not completely explain the
pressor response induced by Ang-(1-7). A comparable
observation was reported by Ross et al. (6), who studied
the stimulatory effect of glutamate in the RVLM. These
authors were able to significantly reduce, but not abolish,
the pressor effect produced by glutamate by using adrener-
gic receptor blockade alone. Only the combination of
adrenergic blockade and VP antagonism was sufficient to
eliminate the cardiovascular effects of glutamate at the
RVLM (6). The participation of VP in the pressor response of
Table 2 - Baseline levels for the mean arterial pressure (MAP, mm Hg) and heart rate (HR, beats/min) before and after
peripheral treatment with autonomic and/or vasopressin receptor antagonists.
Peripheral Treatment Before treatment After treatment
n MAP (mmHg) HR (beats/min) MAP (mmHg) HR (beats/min)
Prazosin 6 116¡7 354¡13 70¡5* 316¡18
Hexamethonium 6 96¡7 319¡16 66¡5* 297¡11*
Atenolol 6 121¡5 352¡8 115¡8 282¡14*
Methyl-atropine 5 105¡8 339¡8 96¡7 423¡14*
VP V1 antagonist 6 106¡4 nd 86¡5 nd
Prazosin+atenolol 6 123¡6 311¡10 67¡5* 254¡266*
Prazosin+methyl-atropine 5 108¡5 347¡20 56¡2* 381¡19*
Methyl-atropine+VP V1 antagonist 4 107¡9 320¡6 84¡4 345¡17*
Prazosin+atenolol+VP V1 antagonist 5 114¡4 316¡26 49¡2* 212¡25*
Hexamethonium+VP V1 antagonist 5 103¡7 339¡8 38¡2* 297¡18*
Prazosin+atenolol+VP V1
antagonist+methyl-atropine
5 111¡9 371¡6 43¡5* 282¡11*
Antagonist doses: prazosin, 90 mg/kg; atenolol, 2.5 mg/kg; methyl-atropine, 2 mg/kg; hexamethonium, 20 mg/kg; vasopressin (VP) V1 receptor antagonist,
10 mg/kg. The MAP and HR values before treatment were obtained 20 minutes after placement of the injector needle into the RVLM. nd = not determined.
*p,0.05 in comparison to before treatment (Student’s t-test).
Figure 1 - Average change in the mean arterial pressure (MAP,
mmHg) produced by bilateral microinjection of Ang-(1-7)
(25 pmol) into the RVLM of control animals (n = 12) or rats
treated with prazosin (90 mg/kg, n = 6); atenolol (2.5 mg/kg,
n = 6); M-atropine (M-atropine, 2.0 mg/kg, n = 5); VP V1 receptor
antagonist (VPa, 10 mg/kg, n = 6); or hexamethonium (20 mg/kg,
n = 6).
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glutamate is consistent with the well-known projections of
RVLM to the hypothalamic nuclei that are involved in the
release of VP, such as projections to the paraventricular
nucleus and supra-optic nucleus (20,25). Interestingly, our
data show that the combination of adrenergic blockade and
VP antagonism produced only a small reduction in the
pressor effect of Ang-(1-7) at the RVLM. These data indicate
that the stimulatory effect of glutamate depends on
Figure 2 - Pulsatile (mmHg; upper panels) and mean (mmHg; lower panels) arterial pressure tracings showing the typical effect of Ang-
(1-7) (25 pmol) microinjection into the RVLM after peripheral treatment with (A) prazosin (90 mg/kg) followed by atenolol (2.5 mg/kg);
(B) prazosin (90 mg/kg) combined with atenolol (2.5 mg/kg) and a VP V1 receptor antagonist (VPa, 10 mg/kg); and (C) prazosin (90 mg/kg)
combined with atenolol (2.5 mg/kg), a VP V1 receptor antagonist (VPa, 10 mg/kg) and methyl-atropine (2.0 mg/kg). Arrows indicate the
end of the microinjection into the RVLM.
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adrenergic and vasopressinergic mechanisms, but factors
other than adrenergic and vasopressinergic mechanisms are
involved in the effects of Ang-(1-7) at the RVLM.
Treatment with the VP V1 receptor antagonist alone did
not alter the pressor effect of Ang-(1-7), as it did not affect
the glutamate response (6). This finding suggests that in the
intact animal, the release of VP stimulated through neurons
projecting from the RVLM can be counterbalanced by
arterial baroreceptor activity induced by the increased
pressure elicited by sympathetic stimulation. This counter-
balancing mechanism would be attenuated in the presence
of a sympathetic blockade.
As a major observation in the present study, only the
combination of ganglionic blockade with a VP V1 receptor
antagonist or the combination of a1 and b1 sympathetic
blockade, VP antagonism and muscarinic receptor blockade
was effective in abolishing the effect of Ang-(1-7) in the
RVLM. These results indicate that in addition to the increase
in sympathetic output and the release of VP, Ang-(1-7)
elicits a reduction of vasodilator tonus at the RVLM that is
susceptible to blockade by M-atropine. At least part of this
vasodilator tonus could be dependent upon hexametho-
nium-insensitive post-synaptic ganglionic receptors.
Another possibility is the involvement of muscarinic
receptors in the heart. Even though we cannot completely
rule out this possibility, it is unlikely because the HR
alterations induced by Ang-(1-7) microinjection into the
RVLM were not consistent, even in animals treated with the
combination of adrenergic blockade and AVP antagonism.
Based on the present knowledge, it is difficult to conceive
that an isolated increase in inotropism elicited by a decrease
in vagal activity would result in an increase in cardiac
output sufficient to explain part of the increase in arterial
pressure.
We have previously shown that the peripheral mechanisms
triggered by angiotensin peptides at the caudal ventrolateral
medulla (CVLM) are also strikingly different (26). The
hypotensive effect of Ang-(1-7) was not accompanied by
significant changes in cardiac output, but it was completely
abolished by peripheral treatment with M-atropine and the
NOS inhibitors L-NAME and 7-NI (26).
It is well known that an active sympathetic neurogenic
vasodilator system exists in the skeletal muscle vasculature
of several species (27-31). Various neurotransmitters and
neuromodulators are active in these neuro-vascular junc-
tions. However, the relative contribution of these neuro-
transmitters is still poorly defined. In addition, there are no
data in the literature that indicate a role of the RVLM in the
modulation of a vasodilator tonus. It has been reported that
centrally mediated activation of the lumbar sympathetic
chain by air-jet stress produces pronounced hindlimb
vasodilation that is mediated by a sympathetic neurogenic
vasodilator system that uses nitric oxide (NO) and/or
related nitrosyl factors (32). In addition, the selective
inhibition of neuronal nitric oxide synthase has been shown
to abolish the vasodilation of the hindlimb induced by the
stimulation of the superior laryngeal nerve (33). Thus, taken
together, these data provide evidence for a novel and
intriguing possibility, i.e., the existence of a functional
vasodilator cholinergic and/or nitrergic sympathetic vas-
cular system that may be modulated by the CVLM/RVLM
neuronal network.
In our study, peripheral treatment with M-atropine alone
did not affect the effect of Ang-(1-7) in the RVLM, which
indicates that the peripheral cholinergic system is not solely
responsible for the effects of Ang-(1-7) in the RVLM. The
participation of central cholinergic receptors in the hypo-
tensive response of Ang-(1-7) is another possibility but
seems unlikely given that M-atropine is a quaternary
ammonium derivative of atropine that lacks a central effect
because of its poor penetration in the brain (34). Another
possibility is that the effect of M-atropine is related to the
blockade of M1 ganglionic receptors. Although we cannot
completely rule out this possibility, it seems unlikely
Figure 3 - Average changes in the mean arterial pressure (MAP, mmHg) produced by bilateral RVLM microinjection of Ang-(1-7)
(25 pmol, n = 12) in control rats or rats treated with (A): prazosin, 90 mg/kg, combined with atenolol, 2.5 mg/kg (n = 5); prazosin, 90 mg/
kg, combined with M-atropine, 2.0 mg/kg (n = 5); M-atropine, 2.5 mg/kg, combined with the VP V1 receptor antagonist (VPa, 10 mg/kg;
n = 4) or (B): prazosin, 90 mg/kg, combined with atenolol, 2.5 mg/kg, and the VP V1 receptor antagonist (VPa), 10 mg/kg (n = 5); prazosin,
90 mg/kg, combined with atenolol, 2.5 mg/kg, VPa, 10 mg/kg and methyl-atropine, 2.0 mg/kg (n = 5); or hexamethonium, 20 mg/kg,
combined with VPa, 10 mg/kg (n = 5). *p,0.05 compared with the effect produced by microinjection of Ang-(1-7) in control, untreated
rats (ANOVA followed by Newman-Keuls test).
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because the dose of M-atropine used alone or in combina-
tion with other autonomic antagonists did not affect the
baseline values for arterial pressure. In the present study,
ganglionic blockade did not inhibit the RVLM pressor effect
of Ang-(1-7). However, hexamethonium completely blocked
the RVLM response induced by Ang II (7,9,35), which
suggests that different pathways are stimulated by Ang II
and Ang-(1-7) in the RVLM.
Finally, an important concern that is always raised in
studies performed on anesthetized animals is the possibility
that altered autonomic outflow interferes with central
responses. In the present study, urethane was chosen on
the basis of previous studies that showed that this anesthetic
has less of an effect than other anesthetics on baroreflex
control and autonomic function (36,37). In addition, we have
previously shown that microinjection of angiotensin pep-
tides into the RVLM induces similar pressor effects in
anesthetized and conscious rats (17,18). Thus, although
anesthesia may alter cardiovascular and respiratory func-
tions, urethane may have had a minor impact on the pressor
responses induced by RVLM microinjections of Ang II and
Ang-(1-7).
In summary, the data presented in this study show that
the pressor effect produced by bilateral microinjection of
Ang-(1-7) into the RVLM of anesthetized rats cannot be
exclusively attributed to an increase in sympathetic drive.
Furthermore, our study opens an interesting possibility that
Ang-(1-7) acts at the RVLM on neuronal cells that modulate
the activity of a vasodilator tonus that is sensitive to atropine.
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